Svedbom, A. http://orcid.org/0000-0003-2596-1679
Hadji, P.
Hernlund, E.
Thoren, R.
McCloskey, E.
Stad, R.
Stollenwerk, B.
Funding for this research was provided by:
Amgen Europe Gmbh
Article History
Received: 19 February 2019
Accepted: 18 June 2019
First Online: 3 July 2019
Compliance with ethical standards
:
: B Stollenwerk and R Stad are Amgen employees and holders of Amgen stocks/options. A Svedbom, E Hernlund, R Thoren were paid consultants to Amgen Europe GmbH through their employment at ICON Clinical Research. ICON Clinical Research has received funding from several pharmaceutical companies involved in the marketing of products for treatment of osteoporosis. P Hadji received research funding and consultancy and lecture fees from the following companies: Amgen, Elli Lilly, Novartis, Gedeon Richter, Pfizer, UCB. E McCloskey has received consultancy and/or speaker’s honoraria and/or research support from ActiveSignal, Amgen, Arthritis Research UK, AstraZeneca, Consilient Healthcare, GSK, Hologic, I3 Innovus, Internis, IOF, Lilly, Medtronic, Merck, MRC, Norvartis, Pfizer, Roch, Sanofi-Aventis, Servier, Synexus, Tethys, UCB, Unilever, and Warner Chilcott.
: None.